Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
- PMID: 27875521
- PMCID: PMC5155370
- DOI: 10.1038/bjc.2016.381
Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
Comment on
-
Trastuzumab-associated cardiac events in the Persephone trial.Br J Cancer. 2016 Dec 6;115(12):1462-1470. doi: 10.1038/bjc.2016.357. Epub 2016 Nov 22. Br J Cancer. 2016. PMID: 27875516 Free PMC article. Clinical Trial.
References
-
- de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WT, Sluiter WJ, van Veldhuisen DJ, Suter TM, Sleijfer DT, Perik PJ (2007) 111-Indium-trastuzumab visualizes myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 43(14): 2046–2051. - PubMed
-
- Earl HM, Vallier A-L, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L (2016) Trastuzumab-associated cardiac events in the Persephone trial. Br J Cancer e-pub ahead of print 22 November 2016 doi:10.1038/bjc.2016.357. - PMC - PubMed
-
- Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 10: 564–575. - PubMed
-
- Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23: 2900–2902. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
